MUSCLE-INVASIVE BLADDER CARCINOMA
Clinical trials for MUSCLE-INVASIVE BLADDER CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new MUSCLE-INVASIVE BLADDER CARCINOMA trials appear
Sign up with your email to follow new studies for MUSCLE-INVASIVE BLADDER CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for bladder cancer patients: drug combo tested in early trial
Disease control CompletedThis early-phase study tested a combination of two drugs—CG0070 (given directly into the bladder) and nivolumab (given through an IV)—in 21 people with muscle-invasive bladder cancer who could not receive the standard chemotherapy drug cisplatin. The main goal was to check safety…
Matched conditions: MUSCLE-INVASIVE BLADDER CARCINOMA
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 17, 2026 03:11 UTC
-
New combo attack on rare bladder cancer shows promise in early trial
Disease control CompletedThis pilot study tested whether giving a combination of immunotherapy (pembrolizumab) and chemotherapy before surgery could help people with rare types of muscle-invasive bladder cancer. 17 participants received the treatment to see if it could eliminate all signs of cancer at th…
Matched conditions: MUSCLE-INVASIVE BLADDER CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 06, 2026 16:14 UTC
-
Bladder cancer breakthrough? tiny DNA fragments may predict treatment success
Knowledge-focused CompletedThis study looked at whether measuring tiny bits of tumor DNA in blood and urine (called ctDNA) is possible in people with muscle-invasive bladder cancer receiving standard treatment. Researchers collected samples before, during, and after therapy to see if ctDNA levels could hel…
Matched conditions: MUSCLE-INVASIVE BLADDER CARCINOMA
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated May 17, 2026 03:14 UTC